Every material Form 8-K Chemed has filed with the SEC since December 18, 2023, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
Chemed Corporation reported third-quarter 2026 revenue of $690.9 million, up 10.6%, with GAAP diluted EPS of $5.45 (up 22.2%) and adjusted diluted EPS of $6.75 (up 28.1%). The company estimates full-year 2026 adjusted EPS will be at or slightly above the high end of its guidance, and Roto-Rooter's adjusted EBITDA declined 2.5%.
Q3 2026 revenue $690.9 million, up 10.6%; GAAP diluted EPS $5.45, up 22.2%; adjusted diluted EPS $6.75, up 28.1%
VITAS net patient revenue $457.4 million, up 12.2%; average daily census 24,428, up 9.4%
Roto-Rooter revenue $233.5 million, up 7.5%; adjusted EBITDA $48.2 million, down 2.5%
Expects full-year 2026 adjusted EPS at or slightly above the high end of guidance; repurchased 125,000 shares for $66.0 million in the quarter
Chemed reported second-quarter 2026 revenue of $673.3 million, up 8.8%, and GAAP diluted EPS of $5.13, up 43.7% from the prior-year quarter. The company raised its full-year 2026 adjusted diluted EPS guidance to $25.00 to $25.75, mainly because VITAS performed better than expected, which benefits shareholders.
Q2 2026 revenue $673.3 million, up 8.8%; adjusted diluted EPS $6.06, up 41.9%
VITAS net patient revenue $443.3 million, up 11.9%; Roto-Rooter revenue $229.9 million, up 3.3%
2026 adjusted diluted EPS guidance raised to $25.00-$25.75 from $24.00-$24.75
Repurchased 210,000 shares for $89.8 million in the quarter; about $139.8 million authorization remains
Chemed reported first-quarter 2026 revenue up 1.6% to $657.5 million, with GAAP diluted EPS of $4.84, down 0.4%, and adjusted diluted EPS of $5.65, up 0.4%. The company raised its full-year 2026 adjusted EPS guidance to $24.00 to $24.75 from $23.25 to $24.25, citing stronger VITAS performance and share repurchases.
Q1 2026 revenue rose 1.6% to $657.5 million; GAAP diluted EPS was $4.84, down 0.4%, and adjusted diluted EPS was $5.65, up 0.4%.
Full-year 2026 adjusted EPS guidance raised to $24.00 to $24.75 from $23.25 to $24.25.
VITAS anticipated ADC growth raised to 4.5% to 5.5% from 3.5% to 4.0%; Roto-Rooter adjusted EBITDA margin guidance lowered to 21.5% to 22.5% from 22.5% to 23.0%.
Repurchased 500,000 shares for $197.7 million in the quarter; about $229.6 million of authorization remained as of March 31, 2026.
Chemed Corporation renewed its $450 million senior secured credit facilities on April 10, 2026, under a Sixth Amended and Restated Credit Agreement. The five-year revolver uses a floating SOFR-based rate with a tiered spread tied to the company's leverage ratio, and includes an option to expand the revolver by an additional $250 million. The filing describes a renewal of existing financing rather than a change in reported results.
Five-year $450 million revolving credit facility, including $100 million for letters of credit
Floating rate generally based on SOFR plus a tiered rate that varies with the company's leverage ratio
Expansion feature allows Chemed to increase the revolver by an additional $250 million
JPMorgan Chase Bank, N.A. served as Administrative Agent; Bank of America, N.A. was Syndication Agent
Chemed reported fourth-quarter 2025 revenue of $639.3 million, essentially flat year over year, while GAAP diluted EPS fell 9.0% to $5.48 and adjusted diluted EPS fell 6.0% to $6.42. The company guided to 2026 adjusted diluted EPS of $23.25 to $24.25, compared with 2025 adjusted EPS of $21.55, and said 55% of 2026 adjusted net income and adjusted EBITDA before Medicare Cap is expected in the second half.
Q4 2025 revenue was $639.3 million, essentially flat; GAAP diluted EPS was $5.48, down 9.0%, and adjusted diluted EPS was $6.42, down 6.0%.
VITAS net patient revenue rose 1.9% to $418.8 million, while Roto-Rooter revenue fell 3.7% to $220.6 million.
2026 guidance: adjusted diluted EPS of $23.25 to $24.25, versus $21.55 in 2025; Roto-Rooter adjusted EBITDA margin expected at 22.5% to 23.0%.
During the quarter the company repurchased 400,000 shares for $174.6 million; $127.3 million of repurchase authorization remained at December 31, 2025.
Chemed reported third-quarter 2025 results for the period ended September 30, 2025, with revenue up 3.1% to $624.9 million while GAAP diluted EPS fell 10.8% to $4.46 and adjusted diluted EPS fell 6.6% to $5.27. The company reiterated its 2025 adjusted diluted EPS guidance of $22.00 to $22.30 per share.
Revenue rose 3.1% to $624.9 million; VITAS net revenue rose 4.2% to $407.7 million and Roto-Rooter revenue rose 1.1% to $217.2 million.
GAAP diluted EPS was $4.46, down from $5.00 a year earlier; adjusted diluted EPS was $5.27, down 6.6%.
Consolidated Adjusted EBITDA was $109.0 million, compared with $123.0 million in the prior-year quarter, per the EBITDA reconciliation.
2025 guidance of $22.00 to $22.30 per share was reiterated and assumes no Medicare Cap for the Florida combined program from October 1, 2025.
Chemed reported second-quarter 2025 revenue up 3.8% to $618.8 million, but GAAP diluted earnings per share fell 23.2% to $3.57. The company cut its full-year 2025 EPS guidance to $22.00 to $22.30 from $24.95 to $25.45, citing a larger Medicare Cap billing limitation at VITAS, and said VITAS CEO Nicholas M. Westfall is resigning, with Joel L. Wherley to succeed him.
Q2 2025 revenue rose 3.8% to $618.8 million; GAAP diluted EPS was $3.57, down 23.2%, and adjusted diluted EPS was $4.27, down 21.9%.
Full-year 2025 EPS guidance revised to $22.00 to $22.30, versus the previously issued $24.95 to $25.45.
VITAS estimates a $19 million Florida Medicare Cap billing limitation for the cap year ending September 30, 2025, and accrued $16.4 million in Q2 2025.
Nicholas M. Westfall resigns as Chairman and CEO of VITAS effective July 29, 2025, and will remain an Executive Vice President through December 1, 2025; Joel L. Wherley will succeed him as VITAS CEO.
Chemed Corporation reported first-quarter 2025 results for the period ended March 31, 2025, with revenue up 9.8% to $646.9 million and GAAP diluted EPS up 14.6% to $4.86. VITAS revenue and profit grew, while Roto-Rooter adjusted EBITDA fell 2.4%, and the company said it will provide updated 2025 earnings guidance with its June 30, 2025 release.
Revenue increased 9.8% to $646.9 million; GAAP diluted EPS was $4.86, up 14.6%.
Adjusted diluted EPS was $5.63, up 8.3%.
VITAS net patient revenue rose 15.1% to $407.4 million; Roto-Rooter revenue rose 1.8% to $239.5 million.
Roto-Rooter adjusted EBITDA fell 2.4% to $59.2 million; the company will update 2025 guidance on June 30, 2025.
Chemed reported fourth-quarter 2024 revenue of $640.0 million, up 9.2%, with GAAP diluted EPS of $6.02, up 2.0%, and adjusted diluted EPS of $6.83, up 3.5%. The company guided to full-year 2025 adjusted diluted EPS of $24.95 to $25.45, compared with $23.13 in 2024, while Roto-Rooter revenue and adjusted EBITDA declined in the quarter.
Q4 2024 revenue $640.0 million, up 9.2%; VITAS net patient revenue up 17.4% to $411.0 million
Roto-Rooter Q4 revenue fell 2.9% to $229.0 million and adjusted EBITDA fell 7.2% to $60.3 million
2025 guidance: adjusted diluted EPS of $24.95 to $25.45 versus $23.13 for 2024; Roto-Rooter revenue growth of 2.4% to 3.0%
Repurchased 388,235 shares for $212.8 million in the quarter; about $255.3 million of authorization remained at December 31, 2024
Chemed reported third-quarter 2024 revenue of $606.2 million, up 7.4%, and adjusted diluted EPS of $5.64, up 6.0%. The company said Roto-Rooter's revenue and adjusted EBITDA were softer than anticipated, and it revised full-year 2024 adjusted EPS guidance to $23.00 to $23.15, which implies a 13.3% to 14.0% increase over 2023's $20.30.
Q3 2024 revenue $606.2 million, up 7.4%; GAAP diluted EPS $5.00, up 1.4%; adjusted diluted EPS $5.64, up 6.0%
VITAS net patient revenue $391.4 million, up 17.3%; Roto-Rooter revenue $214.8 million, down 6.9%
Roto-Rooter adjusted EBITDA $56.4 million, down 15.8%; adjusted EBITDA margin 26.3%, down 275 basis points
Full-year 2024 adjusted EPS guidance $23.00 to $23.15; company repurchased 100,000 shares for $57.8 million in the quarter
Chemed reported second-quarter 2024 revenue of $595.9 million, up 7.6%, and GAAP diluted EPS of $4.65, up 32.5%. The company raised its full-year 2024 adjusted EPS estimate to $23.55-$23.80 from the prior $23.30-$23.70, a higher outlook for shareholders.
Q2 2024 revenue rose 7.6% to $595.9 million; adjusted diluted EPS was $5.47, up 34.1%
VITAS revenue rose 16.7% to $374.6 million, while Roto-Rooter revenue fell 5.0% to $221.3 million
2024 adjusted EPS guidance raised to $23.55-$23.80 from $23.30-$23.70
As of June 30, 2024, cash and cash equivalents were $222.9 million with no current or long-term debt
Chemed reported first-quarter 2024 revenue of $589.2 million, up 5.2%, and GAAP diluted EPS of $4.24, up 18.4%, with VITAS driving the gains while Roto-Rooter revenue fell 5.8%. The company reiterated its full-year 2024 adjusted EPS guidance range of $23.30 to $23.70 and said it will provide updated guidance with its June 30, 2024 results.
Consolidated revenue rose 5.2% to $589.2 million; adjusted diluted EPS was $5.20, up 21.5%.
VITAS net patient revenue rose 14.0% to $354.0 million, and its adjusted EBITDA excluding Medicare Cap rose 67.2% to $60.7 million.
Roto-Rooter revenue fell 5.8% to $235.2 million, and its adjusted EBITDA declined 15.6%.
Full-year 2024 adjusted EPS guidance of $23.30 to $23.70 was reiterated; cash and equivalents were $313.4 million at March 31, 2024, with no debt.
VITAS Healthcare, a wholly owned subsidiary of Chemed, completed its $85 million purchase of substantially all hospice operations and an assisted living facility from Covenant Health and Community Services, effective April 17, 2024. The purchase was made with cash on hand, and the filing does not report financial results from the acquired operations.
Purchase price: $85 million, structured as an asset purchase, funded with cash on hand
Covenant hospice operations span the Florida panhandle and Alabama, including Pensacola, Tallahassee, Panama City and Dothan markets
Transaction was first announced on March 13, 2024 and closed effective April 17, 2024
Chemed reported fourth-quarter 2023 revenue of $585.9 million, up 7.2%, with GAAP diluted EPS of $5.90, up 42.9%, and adjusted diluted EPS of $6.60, up 35.0%. The company gave 2024 adjusted diluted EPS guidance of $23.30 to $23.70, compared with $20.30 in 2023, while Roto-Rooter revenue fell 1.1% in the quarter.
Q4 2023 revenue rose 7.2% to $585.9 million; GAAP diluted EPS was $5.90 and adjusted diluted EPS was $6.60
VITAS net patient revenue rose 13.6% to $350.0 million; Roto-Rooter revenue fell 1.1% to $235.9 million
2024 guidance: adjusted diluted EPS of $23.30 to $23.70 versus $20.30 adjusted EPS in 2023
As of December 31, 2023, cash and cash equivalents were $264.0 million with no current or long-term debt
Chemed granted David P. Williams, who now serves as an advisor to the Chief Executive Officer, 6,424 Performance Share Units and agreed to pay him a monthly salary of $38,750. The units vest into company shares based on Chemed's total shareholder return over the next three calendar years, tying part of his pay to shareholder returns.
Grant of 6,424 Performance Share Units to David P. Williams, dated January 29, 2024
Monthly salary of $38,750 for his role as advisor to the CEO
Units vest into shares depending on total shareholder return over the next three calendar years
Company may terminate his employment on twelve months' written notice
Chemed's board appointed Michael D. Witzeman, the company's Vice President and Controller, as Chief Financial Officer effective January 1, 2024. The change follows the retirement of David P. Williams from the CFO role, and Witzeman will also continue as Controller and Vice President.
Michael D. Witzeman appointed CFO by the board on December 18, 2023, effective January 1, 2024
Replaces David P. Williams, who is retiring from the CFO role
Witzeman joined Chemed in 2005 after Deloitte & Touche LLP and is a licensed CPA
Witzeman will keep his Controller and Vice President roles
Briefs are written by AI from the filing text (each brief's own page names the model) and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the model's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every Chemed filing is on SEC EDGAR ↗. 8-K briefs of other companies →